- Home
- GDEV vs CNTX Comparison
GDEV vs CNTX Comparison
Compare GDEV & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDEV | CNTX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Cyprus | United States |
| Employees | 589 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.9M | 283.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GDEV | CNTX |
|---|---|---|
| Price | $14.15 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 866.0 | ★ 909.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.89 | N/A |
| P/E Ratio | $5.19 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.60 | $0.49 |
| 52 Week High | $42.20 | $3.62 |
Technical Indicators
Market Signals| Indicator | GDEV | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.81 | 55.31 |
| Support Level | $12.18 | $2.07 |
| Resistance Level | $16.62 | N/A |
| Average True Range (ATR) | 0.58 | 0.30 |
| MACD | -0.16 | 0.02 |
| Stochastic Oscillator | 28.67 | 49.68 |
Price Performance
Historical ComparisonAbout GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.